ArticleScientific reports2020

Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.

Yumi Fujimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.